Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894647 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
A Phase 3 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT00894647: Completed Phase 3 study, sponsored by Graceway Pharmaceuticals.
NCT00894647 is a Phase 3 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 247 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00894647, a Phase 3 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
Primary Outcome
The primary efficacy endpoint was a comparison between the active and placebo treatment groups of percent change from baseline in the total AK lesion count at Week 26. All AK lesions on the face were included in the analysis-treated and untreated AK lesions at baseline (defined as the AK lesion count just prior to cryosurgery) and new lesions that appeared post-baseline.
Interventions
- DRUG placebo cream
- DRUG imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
What the finished NCT00894647 record still lists
NCT00894647 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo cream is the first listed.
NCT00894647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00894647 about?
NCT00894647 is a clinical study titled "Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery". The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
What is the current status of trial NCT00894647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2009-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00894647?
The interventions under investigation include: placebo cream (DRUG), imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00894647?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00894647's enrollment target sits among peer trials
247 1266th of 2000 higher than 734 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia